Abstract
Anti-D was evaluated in 8 RhD positive patients (6 males, 2 females) aged 2–21 years (mean 10 years) with idiopathic Thrombocytopenic Purpura (ITP). Five patients with chronic ITP and 3 patients with acute ITP were administered Anti-D in the dosage of 50 ug/kg intramuscularly (IM) for 3 consecutive days. One patient of chronic ITP received two courses of Anti-D. Patients were followed up for 7 to 16 months (mean 9 months). All three cases of acute ITP had a complete response and are in remission between 3 to 12 months of follow up. Two of five cases of chronic ITP had a partial response. Rise in platelet count was observed within 72–124 hours, and duration of response varied between 10 to 15 days. None of these patients had any significant side effects of anti-D immunoglobulin therapy. Intramuscular administration of anti-D is safe, effective and low cost alternative to IVlgG in the treatment of acute ITP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Karpatkin S. Autoimmune thrombocytopenia.Semin Hematol 1985; 22: 260–288.
Imbach P, Barandin SD, Apuzzo V et al. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.Lancet 1981; 1: 1228–1230.
Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults immune thrombocytopenic purpura: A review of literature.Vox Sanguinis 1985; 52: 206–211.
Imholz B, Imbach P, Baumgartner C et al. Intravenous immunoglobulin (IVIG) for previously untreated acute and chronic idiopathic thrombocytopenic purpura in childhood: A multicentre prospective study.BLUT 1988; 52: 63–69.
Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia.Lancet 1991; 2: 1983–1984.
Salama A, Kiefel V, Mueller-Eckharadt. Treatment of autoimmune thrombocytopenic purpura with Rhesus antibodies (Anti-RhD).BLUT 1984; 49: 29.
Bacher T, Kuenzlen E, Salama A et al. Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (Anti-D).Eur J Paediatr 1986; 145: 166–169.
Boughton BJ, Chakravorty R, Baglin TP et al. The treatment of chronic idiopathic thrombocytopenic purpure with anti-d (RhD) immunoglobulin: Its effectiveness; safety and mechanism of action.Clin Lab Hematol 1988; 10: 275–284.
Bussel JB, Graziano JV, Kumbely RP et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity and mechanism of effect.Blood 1991; 77 (9): 1884–1893.
Andrew M, Blanchette VS, Adame M et al. A multicentre study of childhood chronic idiopathic thrombocytopenic purpura with anti-D.J Pediatr 1992; 120 (4): 522–527.
Chown B, Bowman JM, Pollock J et al. The effects of anti-D IgG and O positive recipients.Can Med Assoc J 1970; 102: 1151–1164.
Sansome G, Veneziano G. Erroneous administration of anti-D gammaglobulin to new born children.Lancet 1970; 1: 952.
Boughton BJ, Chakravorty RK, Simpson A et al. The effect of anti-Rh (O) D and non specific immunoglobulin on monocyte of receptor function. The role of high molecular weight IgG polymers and IgG subclass.Clin Lab Hematol 1990; 12: 17–23.
Berkman GA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulin.Semin Hematol 1988; 25 (2): 140–158.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krishnamurti, L., Charan, V.D., Desai, N. et al. Anti-D immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. Indian J Pediatr 61, 179–182 (1994). https://doi.org/10.1007/BF02843613
Issue Date:
DOI: https://doi.org/10.1007/BF02843613